Notably, TREM2 overexpression in SNCA-A53T transgenic mouse models restored microglial synaptic pruning capacity and reduced dopaminergic neuron loss, identifying TREM2 as a critical therapeutic target for modulating neuroinflammation in PD.115. The gene discussed is TREM2; the disease is Parkinson disease.